Pharmaceutical

Ionis and Sobi agree on olezarsen commercialisation

Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.

Mar 29, 2025 - 06:00
Ionis and Sobi agree on olezarsen commercialisation
Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.
Read the original article

Tags:

Previous Article

How bioconjugation is unlocking the next generation of drug development

Next Article

Blockbuster potential drugs ruled the 2024 pipeline with 53% rise over 2023

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

PTC Therapeutics gets grant for treatment of huntington...

Mar 30, 2024

STAT+: Most of Canada’s public research universities get bad grades for ensuring access to drugs they discover

STAT+: Most of Canada’s public research universities ge...

May 1, 2023

China grants EUA to Covid-19 vaccine against XBB descendent lineages

China grants EUA to Covid-19 vaccine against XBB descen...

Jun 9, 2023